Skip to main content

Table 3 Expected number of epoetin SEB users in Canada, years 1 to 5

From: A budget impact analysis of the introduction of erythropoiesis stimulating agent subsequent entry biologics for the treatment of anemia of chronic kidney disease in Canada

  Year 1 Year 2 Year 3 Year 4 Year 5
Number of SEB users 982 4,393 8,344 13,785 17,826
  1. SEB = subsequent entry biologic.